Abstract

BackgroundN6-methyladenosine (m6A) modification is the most common chemical modification in mammalian mRNAs, and it plays important roles by regulating several cellular processes. Previous studies report that m6A is implicated in modulating tumorigenesis and progression. However, dysregulation of m6A modification and effect of m6A demethylase fat-mass and obesity-associated protein (FTO) on glucose metabolism has not been fully elucidated in papillary thyroid cancer (PTC).MethodsQuantitative real-time PCR (qRT-PCR), western blotting and immunohistochemistry were performed to explore the expression profile of FTO in PTC tissues and adjacent non-cancerous thyroid tissues. Effects of FTO on PTC glycolysis and growth were investigated through in vitro and in vivo experiments. Mechanism of FTO-mediated m6A modification was explored through transcriptome-sequencing (RNA-seq), methylated RNA immunoprecipitation sequencing (MeRIP-seq), MeRIP-qPCR, luciferase reporter assays, RNA stability assay and RNA immunoprecipitation assay.ResultsFTO expression was significantly downregulated in PTC tissues. Functional analysis showed that FTO inhibited PTC glycolysis and growth. Further analyses were conducted to explore FTO-mediated m6A modification profile in PTC cells and Apolipoprotein E (APOE) was identified as the target gene for FTO-mediated m6A modification using RNA-seq and MeRIP-seq. FTO knockdown significantly increased APOE mRNA m6A modification and upregulated its expression. FTO-mediated m6A modification of APOE mRNA was recognized and stabilized by the m6A reader IGF2BP2. The findings showed that APOE also promoted tumor growth through glycolysis in PTC. Analysis showed that FTO/APOE axis inhibits PTC glycolysis by modulating IL-6/JAK2/STAT3 signaling pathway.ConclusionFTO acts as a tumor suppressor to inhibit tumor glycolysis in PTC. The findings of the current study showed that FTO inhibited expression of APOE through IGF2BP2-mediated m6A modification and may inhibit glycolytic metabolism in PTC by modulating IL-6/JAK2/STAT3 signaling pathway, thus abrogating tumor growth.

Highlights

  • N6-methyladenosine ­(m6A) modification is the most common chemical modification in mammalian messenger RNA (mRNA), and it plays important roles by regulating several cellular processes

  • Abnormal ­m6A modification is observed and fat-mass and obesity-associated protein (FTO) is downregulated in papillary thyroid cancer (PTC) To explore the role of the m­ 6A modification in PTC, differential expression of ­m6A modification enzymes was determined in PTC tissues and normal thyroid tissues using public clinical databases including The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO)

  • Analysis using TCGA dataset showed that mRNA of the methylases methyltransferase-like 3 (METTL3), methyltransferase-like 14 (METTL14) and Wilms tumor associated protein (WTAP), as well as the demethylases FTO and Alkylation repair homolog protein 5 (ALKBH5) were significantly downregulated in PTC tissues compared with the expression level in normal tissues (Fig. 1a)

Read more

Summary

Introduction

N6-methyladenosine ­(m6A) modification is the most common chemical modification in mammalian mRNAs, and it plays important roles by regulating several cellular processes. Thyroid cancer is the most prevalent malignant tumor of the endocrine system, and its global incidence has been increasing significantly over the past decades [1]. The global cancer statistics in 2020 ranked thyroid cancer incidence as the 9th leading cancer cases among malignant tumors. Incidence of thyroid cancer in China is approximately twice the world average, and is the 7th leading cause of malignant tumors in the country [2]. 95% of the pathological types of thyroid cancer are composed of differentiated thyroid cancer (DTC), and the most common pathological subtype of DTC is papillary thyroid cancer (PTC) [3]. The specific molecular mechanism for occurrence and development of PTC has not been fully elucidated. There is need to explore the molecular mechanism underlying occurrence and development of PTC, and to identify new diagnostic and therapeutic targets for PTC

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call